Findings

What do systematic reviews say?

280 questions · 280 findings · 13 reviews · Cystic Fibrosis and Genetic Disorders

Sort:Best matchNewest Highest certainty Download CSV

No studies found 127 · 45.4%GRADE not reported 3 · 1.1%Very low 85 · 30.4%Low 46 · 16.4%Moderate 19 · 6.8%High 0 · 0%

Colchicine (oral) vs placebo

Acute‐phase response · people with familial Mediterranean fever

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for reducing inflammation in familial Mediterranean fever 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Rilonacept vs placebo

Number of participants experiencing an attacka · people with familial Mediterranean fever

Rilonacept showed no clear difference in number of participants experiencing an attacka compared with placebo (moderate certainty).

1 finding from 1 review

Interventions for reducing inflammation in familial Mediterranean fever 2022 · Cochrane Headline outcomes only
RR 0.87 [0.59, 1.26]
1 study · 14 participants
Moderate

Rilonacept vs placebo

Duration of attacksa · people with familial Mediterranean fever

1 finding from 1 review

Interventions for reducing inflammation in familial Mediterranean fever 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 14 participants
Low

Rilonacept vs placebo

Time between attacks · people with familial Mediterranean fever

1 finding from 1 review

Interventions for reducing inflammation in familial Mediterranean fever 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 14 participants
Low

Isoxsuprine vs placebo

Ulcer healing · individuals with sickle cell disease and a leg ulcer

It is very uncertain whether isoxsuprine changes complete leg ulcer closure (defined as 100% epithelization or skin… compared with placebo (very low certainty).

1 finding from 1 review

Interventions for treating leg ulcers in people with sickle cell disease 2021 · Cochrane Headline outcomes only
RR 1.2 [0.4, 3.62]
1 study · 40 participants
Very low

Arginine butyrate plus standard care alone vs usual care

Change in ulcer size · individuals with sickle cell disease and a leg ulcer

1 finding from 1 review

Interventions for treating leg ulcers in people with sickle cell disease 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 23 participants
Very low

Arginine butyrate plus standard care alone vs usual care

Ulcer‐free survival following treatment for SCLU (free from leg ulcer recurrence) ‐ not reported · individuals with sickle cell disease and a leg ulcer

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for treating leg ulcers in people with sickle cell disease 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Arginine butyrate plus standard care alone vs usual care

Quality of life ‐ not reported · individuals with sickle cell disease and a leg ulcer

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for treating leg ulcers in people with sickle cell disease 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Arginine butyrate plus standard care alone vs usual care

Amputation ‐ not reported · individuals with sickle cell disease and a leg ulcer

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for treating leg ulcers in people with sickle cell disease 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Arginine butyrate plus standard care alone vs usual care

Adverse events · individuals with sickle cell disease and a leg ulcer

1 finding from 1 review

Interventions for treating leg ulcers in people with sickle cell disease 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 23 participants
GRADE not reported

Propionyl‐L‐carnitine vs placebo

Complete leg ulcer closure ‐ not reported · individuals with sickle cell disease and a leg ulcer

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for treating leg ulcers in people with sickle cell disease 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Propionyl‐L‐carnitine vs placebo

Time to ulcer closure ‐ not reported · individuals with sickle cell disease and a leg ulcer

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for treating leg ulcers in people with sickle cell disease 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Propionyl‐L‐carnitine vs placebo

Change in ulcer size · individuals with sickle cell disease and a leg ulcer

1 finding from 1 review

Interventions for treating leg ulcers in people with sickle cell disease 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 15 participants
Very low

Propionyl‐L‐carnitine vs placebo

Ulcer‐free survival following treatment for SCLU (free from leg ulcer recurrence) ‐ not reported · individuals with sickle cell disease and a leg ulcer

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for treating leg ulcers in people with sickle cell disease 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Propionyl‐L‐carnitine vs placebo

Quality of life ‐ not reported · individuals with sickle cell disease and a leg ulcer

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for treating leg ulcers in people with sickle cell disease 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Isoxsuprine vs placebo

Time to ulcer closure ‐ not reported · individuals with sickle cell disease and a leg ulcer

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for treating leg ulcers in people with sickle cell disease 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Propionyl‐L‐carnitine vs placebo

Amputation ‐ not reported · individuals with sickle cell disease and a leg ulcer

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for treating leg ulcers in people with sickle cell disease 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Propionyl‐L‐carnitine vs placebo

Adverse events ‐ not measured · individuals with sickle cell disease and a leg ulcer

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for treating leg ulcers in people with sickle cell disease 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

RGD peptide matrix vs placebo

Complete closureUlcer area was determined by computerized planimetry · individuals with sickle cell disease and a leg ulcer

It is very uncertain whether RGD peptide matrix changes complete closureUlcer area was determined by computerized planimetry compared with placebo (very low certainty).

1 finding from 1 review

Interventions for treating leg ulcers in people with sickle cell disease 2021 · Cochrane Headline outcomes only
RR 0.4 [0.15, 1.04]
1 study · 55 participants
Very low

RGD peptide matrix vs placebo

Time to ulcer closure ‐ not reported · individuals with sickle cell disease and a leg ulcer

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for treating leg ulcers in people with sickle cell disease 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found